Are Edwards Lifesciences Corporation (EW) stocks a prudent buy?

As of right now, Edwards Lifesciences Corporation [EW] is trading at $84.17, climbing down -1.23%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The EW shares have lost -11.29% over the last week, with a monthly amount drifted -10.60%, and not seem to be holding up well over a long-time horizon.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


On 17, September 2022, EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL. In a post published today on Yahoo Finance, Edwards Lifesciences Corporation (NYSE: EW) announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary transcatheter edge-to-edge repair (TEER) therapies. The study confirms TEER as a safe and effective therapy in patients with degenerative mitral regurgitation (DMR). Results from the CLASP IID pivotal trial were presented as a late-breaking clinical science session at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, and published simultaneously in JACC: Cardiovascular Interventions.

From an analyst’s perspective:

Edwards Lifesciences Corporation [NYSE: EW] stock has seen the most recent analyst activity on July 29, 2022, when Canaccord Genuity downgraded its rating to a Hold and also revised its price target to $106 from $115. Previously, Truist started tracking the stock with Buy rating on April 13, 2022, and set its price target to $145. On April 06, 2022, Wolfe Research initiated with a Outperform rating and assigned a price target of $134 on the stock. Bernstein upgraded its rating to a Outperform and increased its price target to $135 on March 16, 2022. UBS upgraded its rating to Buy for this stock on February 02, 2022, and upped its price target to $126. In a note dated January 27, 2022, UBS reiterated an Neutral rating on this stock and revised its target price from $125 to $121.

Through the last year, Edwards Lifesciences Corporation’s stock price ranged from $85.18 to $131.73. Edwards Lifesciences Corporation [NYSE: EW] shares were valued at $84.17 at the most recent close of the market.

Analyzing the EW fundamentals

For Apple Inc, (EW), the latest quarter sales were 1.37 billion, which represents an -0.20% decrease. Gross Margin for this corporation currently stands at +76.57% with Operating Margin at +30.78%, Pretax Margin comes in at +32.53%, and Net Margin reading is +28.73%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 83.27 points at the first support level, and at 82.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 85.23, and for the 2nd resistance point, it is at 86.28.

Edwards Lifesciences Corporation [EW] reported earnings per share of $0.63 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.64/share, meaning a difference of $-0.01 and a surprise factor of -1.60%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were $0.6 per share as compared to estimates of $0.57 per share, a difference of $0.03 representing a surprise of 5.30%.

Ratios To Look Out For

It is important to note that Edwards Lifesciences Corporation [NYSE:EW] has a current ratio of 3.40. As well, the Quick Ratio is 2.38, while the Cash Ratio is 1.42. Considering the valuation of this stock, the price to sales ratio is 15.63, the price to book ratio is 13.85 and the P/E (TTM) ratio is 36.42.

Transactions by insiders

Insider trading has also been a hot topic recently, with 11 insiders purchasing 117,491 shares and 16 selling 96,170 shares in the past 3 months. Recent insider trading involved MUSSALLEM MICHAEL A, Chairman & CEO, that happened on Sep 22 when 19875.0 shares were sold. CVP,Strategy/Corp Development, BOBO DONALD E JR completed a deal on Sep 08 to sell 6725.0 shares. Meanwhile, CVP, TAVR Wood Larry L sold 7242.0 shares on Sep 06.